Back to News
Market Impact: 0.15
Enlivex Randomizes 135 Patients In Phase 2b Knee Arthritis Trial; Data Due By Mid-2027
Source: Nasdaq
Healthcare & Biotech
Enlivex said it has randomized 135 of the planned 182 patients in its Phase 2b trial of Allocetra for moderate-to-severe age-related symptomatic primary knee osteoarthritis. The update reports trial enrollment progress but provides no efficacy or safety results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
ENLV0.10
More News
- Daiichi Sankyo’s first-half profit rises on cancer drug growth; shares up
- We're raising our price target on Eli Lilly as the obesity-drug boom rolls on
- ATEC Q3 2026 slides show profitability surge despite execution gaps
- West Pharma earnings show it's more than a GLP-1 play. Why we see more upside
- Linde delivers a good quarter and puts in a fix for an overhang on the stock
- Aspen Neuroscience prices IPO at $15 per share